Novel Anti-Melanoma Immunotherapies: Disarming Tumor Escape Mechanisms by Sivan Sapoznik, Ohad Hammer, Rona Ortenberg, Michal J. Besser, Tehila Ben-Moshe, Jacob Schachter, Gal Markel

Get full text

Clinical outcomes following PD-1 inhibitor elective discontinuation in cutaneous squamous cell carcinoma: exploring treatment de-escalation by Itamar Averbuch, Nofar Edri, Nethanel Asher, Gal Markel, Daniel Hendler, Hadas Ditzian Kugler, Eyal Yosefof, Noga Kurman

Get full text

TMED inhibition suppresses cell surface PD-1 expression and overcomes T cell dysfunction by Gal Markel, Michal J Besser, Eytan Ruppin, Oscar Krijgsman, Daniel S Peeper, Judit Díaz-Gómez, Ettai Markovits, David W Vredevoogd, Georgi Apriamashvili, Pierre L Levy, Sanju Sinha, Zowi R Huinen, Nils L Visser, Beaunelle de Bruijn, Julia Boshuizen, Susan E van Hal-van Veen, Maarten A Ligtenberg, Onno B Bleijerveld, Chun-Pu Lin, Santiago Duro Sánchez, Juan Simon Nieto, Alex van Vliet, Maarten Altelaar

Get full text